The combination of Tadalafil, silodosin, and paroxetine is effective in the treatment of premature ejaculation.
Phase 2
- Conditions
- Mental and Behavioural Disorders
- Registration Number
- PACTR202211709374727
- Lead Sponsor
- zyvran pharmaceuticals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
1)Ages 18-49 (include 18 and 49) years old male
2)Have sexual intercourse with female on a regular basis (at least twice a week)
3)Intra-vaginal Latency Time (IVLT) < 1 min consistently for at least one year
Exclusion Criteria
1)Use of Certain medications/agents (e.g., Nitrates, other antihypertensive, grapefruit juice)
2)Known hypersensitivity to study agents
3)Current or history of kidney disease. GFR< 50
4)Recent History of MI
5)History of Erectile dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IELT at 3 weeks and 5 weeks compared with placebo
- Secondary Outcome Measures
Name Time Method Clinical Global Impression of Change